Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
4.490
-0.040 (-0.88%)
At close: Mar 9, 2026, 4:00 PM EDT
4.570
+0.080 (1.78%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Company Description
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Atossa Therapeutics, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Nov 8, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Steven Quay |
Contact Details
Address: 107 Spring Street Seattle, Washington 98104 United States | |
| Phone | 206 588 0256 |
| Website | atossatherapeutics.com |
Stock Details
| Ticker Symbol | ATOS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001488039 |
| CUSIP Number | 04962H704 |
| ISIN Number | US04962H7044 |
| Employer ID | 26-4753208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Mark Daniel CPA | Chief Financial Officer |
| Janet Rose Rea MSPH, RAC | Senior Vice President of Research and Development |
| Delly Behen P.H.R. | Senior Vice President of Business Operations |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | 8-K | Current Report |
| Feb 20, 2026 | 424B5 | Filing |
| Feb 20, 2026 | 424B3 | Prospectus |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 11, 2026 | 8-K | Current Report |
| Jan 26, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 8-K | Current Report |
| Jan 6, 2026 | 8-K | Current Report |
| Dec 22, 2025 | DEF 14A | Other definitive proxy statements |
| Dec 12, 2025 | PRE 14A | Other preliminary proxy statements |